Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study

Overview of attention for article published in Blood, November 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

news: 2 news outlets

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 2 news stories from 2 outlets.

AZD0120 Displays Early Responses/Manageable Safety in R/R Multiple Myeloma

Cancer Network, 09 Dec 2025

AZD0120, a dual BCMA and CD19-targeted CAR T-cell therapy, displayed early responses and a manageable safety profile in…

Dual BCMA/CD19 CAR T-cell Therapy AZD0120 Shows Promise for Multiple Myeloma

OncLive, 08 Dec 2025

Treatment with the dual BCMA and CD19-targeted CAR T-cell therapy AZD0120 showed early responses and a tolerable safety profile…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.